Migraine Headache

Neurology

Prevalence

15000.0 / 100K

Incidence

1500.0 / 100K/yr

10 drugs in development·6 companies·0 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
almotriptan malate	Mylan II B.V. (MYL)
divalproex	Teva Pharmaceutical Industries Limited (TEVA)
inFoods® (IBS)	BIOMERICA INC (BMRA)
sumatriptan	Mylan II B.V. (MYL)
trudhesa	IPI Legacy Liquidation Co (IMPL)
ubn relief	HEALTHY EXTRACTS INC. (HYEX)

Unknown(1)

Drug	Company
InFoods® platform (other disease targets)	BIOMERICA INC (BMRA)

N/A(1)

Drug	Company
prochlorperazine and benadryl IV	UNITED THERAPEUTICS Corp (UTHR)

Phase 4(2)

Drug	Company
Diphenhydramine	UNITED THERAPEUTICS Corp (UTHR)
Haloperidol	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 10 drugs in development for Migraine Headache across 6 companies.

The estimated prevalence of Migraine Headache is approximately 15000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.